Frontlight ResearchEarly access
CompletedNo phase
Assessment of the Adjuvant Role of Dietary Supplementation of Antibiotic-tolerant Probiotics in Standard Therapy for the Eradication of Helicobacter Pylori Infection.
Key facts
- Who runs it
- IBSA Farmaceutici Italia Srl
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 270 people enrolled
- Started
- 3 Jul 2024
- Ended
- 5 May 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- IBSA Probiotics
- Placebo
- Record updated
- 8 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Diagnosis of H. pylori infection by breath test and histological and/or cultural examination on biopsy (performed within 10 days prior to T0)
- Prescription of eradication therapy for HP
- Naïve patients (who have never had eradication therapy for H. pylori)
- Patients with symptoms of upper gastrointestinal tract
- Obtaining informed consent
Who cannot take part
- Patients with history of previous eradication attempts
- Patients with known gastric disease (e.g. atrophic gastritis, gastric cancer)
- Patients with severe organ dysfunction (cirrhosis of the liver, severe renal or respiratory failure, dialysis)
- Women who are pregnant or breastfeeding
- Patients unable to provide informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Randomized, double-blind, placebo-controlled clinical study to assess the adjuvant role of dietary supplementation of antibiotic-tolerant probiotics, derived from Lactobacillus acidophilus and Bifidobacterium animalis, in standard therapy for the eradication of Helicobacter pylori infection.
The 2 groups in the trial
- Control groupPlacebo, for comparison
Patients under H. pylori eradication therapy and placebo as treatment
Treatment: Placebo
- Treated groupTreatment being tested
Patients under H. pylori eradication therapy and probiotics as treatment
Treatment: IBSA Probiotics
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Adjuvant Role of Dietary Supplementation of Antibiotic-tolerant Probiotics in Standard Therapy for the Eradication of Helicobacter Pylori Infection.
- Record updated
- 8 July 2025